Pub Date : 2026-03-19DOI: 10.1183/13993003.01890-2025
Afolarin A Otunla,Kumaran Shanmugarajah,Ghazel Mukhtar,Sarah Nabulsi,Daniel Dolan,Justin Salciccioli,Dominic C Marshall,Maria Lucia Madariaga,Joseph Shalhoub
BACKGROUNDLung transplantation offers definitive treatment for end-stage pulmonary disease, but graft survival remains inferior to other solid organ transplants. A key driver of graft loss is antibody-mediated rejection triggered by donor-recipient HLA mismatch. Although HLA matching is not currently used in lung allocation due to organ scarcity and urgency of transplant, understanding its impact could improve risk stratification and outcomes. This study aimed to assess the effect of HLA compatibility on lung graft survival using a large multicenter database, and to explore whether this relationship varies by transplant indication.METHODSWe conducted a retrospective cohort study of 37,091 lung transplant recipients in the UNOS/OPTN database. Patients were grouped by HLA mismatch (0-2 versus 3-6) and stratified by indication. Multivariate Cox regression and Kaplan-Meier analyses assessed adjusted associations with graft survival.FINDINGSHLA-DR mismatch was associated with increased graft failure risk at one year (HR 1.38; 95% CI 1.00-1.90; p=0.048) and five years (HR 1.20; 95% CI 1.03-1.40; p=0.020). Stratified analyses showed this effect was found exclusively in those with COPD or interstitial pneumonia. In COPD, HLA-DR mismatch significantly increased failure risk at one and five years (HR 2.88, CI 1.34-6.19, p=0.007; HR 1.14, CI 1.03-1.40, p=0.020). In interstitial pneumonia, five-year graft failure risk also rose with mismatch (HR 1.28; CI 1.03-1.58; p=0.026).INTERPRETATIONThe present study is the first to demonstrate that HLA-DR mismatch adversely affects lung graft survival in an indication-specific manner. This finding supports the development of indication-specific strategies in post-transplant surveillance and immunosuppression.
肺移植为终末期肺部疾病提供了明确的治疗方法，但移植物的存活率仍然不如其他实体器官移植。移植损失的一个关键驱动因素是由供体-受体HLA不匹配引发的抗体介导的排斥反应。尽管由于器官稀缺和移植的紧迫性，HLA匹配目前尚未用于肺分配，但了解其影响可以改善风险分层和结果。本研究旨在利用大型多中心数据库评估HLA相容性对肺移植存活的影响，并探讨这种关系是否因移植指征而异。方法我们对UNOS/OPTN数据库中的37,091名肺移植受者进行了回顾性队列研究。患者按HLA不匹配（0-2对3-6）分组，按适应证分层。多变量Cox回归和Kaplan-Meier分析评估了与移植物存活的调整相关性。发现shla - dr不匹配在1年（HR 1.38; 95% CI 1.00-1.90; p=0.048）和5年（HR 1.20; 95% CI 1.03-1.40; p=0.020）与移植物衰竭风险增加相关。分层分析显示，这种效应仅在COPD或间质性肺炎患者中发现。在COPD患者中，HLA-DR不匹配显著增加了1年和5年的衰竭风险（HR 2.88, CI 1.34-6.19, p=0.007; HR 1.14, CI 1.03-1.40, p=0.020）。在间质性肺炎中，5年移植物失败的风险也随着失配而增加（HR 1.28; CI 1.03-1.58; p=0.026）。本研究首次证明HLA-DR不匹配以适应症特异性的方式对肺移植存活产生不利影响。这一发现支持移植后监测和免疫抑制的适应症特异性策略的发展。
{"title":"The influence of HLA matching on graft survival in lung transplant recipients is indication specific: An UNOS database analysis.","authors":"Afolarin A Otunla,Kumaran Shanmugarajah,Ghazel Mukhtar,Sarah Nabulsi,Daniel Dolan,Justin Salciccioli,Dominic C Marshall,Maria Lucia Madariaga,Joseph Shalhoub","doi":"10.1183/13993003.01890-2025","DOIUrl":"https://doi.org/10.1183/13993003.01890-2025","url":null,"abstract":"BACKGROUNDLung transplantation offers definitive treatment for end-stage pulmonary disease, but graft survival remains inferior to other solid organ transplants. A key driver of graft loss is antibody-mediated rejection triggered by donor-recipient HLA mismatch. Although HLA matching is not currently used in lung allocation due to organ scarcity and urgency of transplant, understanding its impact could improve risk stratification and outcomes. This study aimed to assess the effect of HLA compatibility on lung graft survival using a large multicenter database, and to explore whether this relationship varies by transplant indication.METHODSWe conducted a retrospective cohort study of 37,091 lung transplant recipients in the UNOS/OPTN database. Patients were grouped by HLA mismatch (0-2 versus 3-6) and stratified by indication. Multivariate Cox regression and Kaplan-Meier analyses assessed adjusted associations with graft survival.FINDINGSHLA-DR mismatch was associated with increased graft failure risk at one year (HR 1.38; 95% CI 1.00-1.90; p=0.048) and five years (HR 1.20; 95% CI 1.03-1.40; p=0.020). Stratified analyses showed this effect was found exclusively in those with COPD or interstitial pneumonia. In COPD, HLA-DR mismatch significantly increased failure risk at one and five years (HR 2.88, CI 1.34-6.19, p=0.007; HR 1.14, CI 1.03-1.40, p=0.020). In interstitial pneumonia, five-year graft failure risk also rose with mismatch (HR 1.28; CI 1.03-1.58; p=0.026).INTERPRETATIONThe present study is the first to demonstrate that HLA-DR mismatch adversely affects lung graft survival in an indication-specific manner. This finding supports the development of indication-specific strategies in post-transplant surveillance and immunosuppression.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"6 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-19DOI: 10.1183/13993003.01878-2025
Hyungjin Kim,Eunseo Jo,Jinseob Kim,Soon Ho Yoon,Anna J Podolanczuk,Christopher J Ryerson
BACKGROUNDHigh-density lipoprotein (HDL) cholesterol exerts anti-inflammatory, antioxidative, and endothelial-protective effects, yet its role in interstitial lung abnormalities (ILA) remains unclear.METHODSWe analyzed baseline screening from heavy smokers who participated in the Korean national lung cancer screening program (2019-2021). HDL cholesterol was measured at two prescreening time points (remote and immediate) and categorized as normal or low. Participants were also classified into four HDL trajectories: normal-to-normal, low-to-normal, normal-to-low, and low-to-low. We used logistic regression to estimate odds ratios (ORs) for ILA, adjusting for demographic characteristics, body mass index, lifestyle factors, comorbidities, income status, lipid profiles, and statin use.RESULTSAmong 159 729 participants (mean age, 61.7 years; 98.2% men), ILA was detected in 2.9%, with higher prevalence in those with low HDL at immediate prescreening compared with normal HDL (3.5% versus 2.7%). Participants with low HDL cholesterol had a higher proportion of obesity (6.1% versus 3.5%) and more frequent statin use (40.0% versus 34.4%) than those with normal HDL cholesterol. Compared with the normal-to-normal group (2.6%), ILA prevalence increased across the low-to-normal (3.1%), normal-to-low (3.5%), and low-to-low (3.6%) groups. Low HDL at immediate prescreening was associated with a 28% higher risk of ILA (95% CI, 1.19-1.38; p<0.001). Compared with normal-to-normal HDL, the odds of ILA were higher in low-to-normal (adjusted OR, 1.17; 95% CI, 1.06-1.29; p=0.002), normal-to-low (adjusted OR, 1.30; 95% CI, 1.18-1.44; p<0.001), and low-to-low groups (adjusted OR, 1.32; 95% CI, 1.20-1.45; p<0.001).CONCLUSIONSLow HDL cholesterol was associated with a higher risk of ILA.
{"title":"Associations between High-Density Lipoprotein Cholesterol and Interstitial Lung Abnormalities in the Korean National Lung Cancer Screening.","authors":"Hyungjin Kim,Eunseo Jo,Jinseob Kim,Soon Ho Yoon,Anna J Podolanczuk,Christopher J Ryerson","doi":"10.1183/13993003.01878-2025","DOIUrl":"https://doi.org/10.1183/13993003.01878-2025","url":null,"abstract":"BACKGROUNDHigh-density lipoprotein (HDL) cholesterol exerts anti-inflammatory, antioxidative, and endothelial-protective effects, yet its role in interstitial lung abnormalities (ILA) remains unclear.METHODSWe analyzed baseline screening from heavy smokers who participated in the Korean national lung cancer screening program (2019-2021). HDL cholesterol was measured at two prescreening time points (remote and immediate) and categorized as normal or low. Participants were also classified into four HDL trajectories: normal-to-normal, low-to-normal, normal-to-low, and low-to-low. We used logistic regression to estimate odds ratios (ORs) for ILA, adjusting for demographic characteristics, body mass index, lifestyle factors, comorbidities, income status, lipid profiles, and statin use.RESULTSAmong 159 729 participants (mean age, 61.7 years; 98.2% men), ILA was detected in 2.9%, with higher prevalence in those with low HDL at immediate prescreening compared with normal HDL (3.5% versus 2.7%). Participants with low HDL cholesterol had a higher proportion of obesity (6.1% versus 3.5%) and more frequent statin use (40.0% versus 34.4%) than those with normal HDL cholesterol. Compared with the normal-to-normal group (2.6%), ILA prevalence increased across the low-to-normal (3.1%), normal-to-low (3.5%), and low-to-low (3.6%) groups. Low HDL at immediate prescreening was associated with a 28% higher risk of ILA (95% CI, 1.19-1.38; p<0.001). Compared with normal-to-normal HDL, the odds of ILA were higher in low-to-normal (adjusted OR, 1.17; 95% CI, 1.06-1.29; p=0.002), normal-to-low (adjusted OR, 1.30; 95% CI, 1.18-1.44; p<0.001), and low-to-low groups (adjusted OR, 1.32; 95% CI, 1.20-1.45; p<0.001).CONCLUSIONSLow HDL cholesterol was associated with a higher risk of ILA.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"7 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-12DOI: 10.1183/13993003.02167-2025
Raj C Dedhia,Brendan T Keenan
{"title":"More correlates - not predictors - of hypoglossal nerve stimulation effectiveness.","authors":"Raj C Dedhia,Brendan T Keenan","doi":"10.1183/13993003.02167-2025","DOIUrl":"https://doi.org/10.1183/13993003.02167-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"76 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Transthoracic shear-wave elastography (SWE) facilitates differentiation between benign and malignant lesions. This pragmatic randomised controlled trial aimed to validate the effectiveness and safety of SWE-guided transthoracic biopsy for diagnosing subpleural lung lesions.
Methods: Eligible patients with peripheral lung lesions suspicious for lung malignancy and suitable for biopsy were randomised in a 1:1 ratio to the SWE-guided or conventional ultrasound-guided transthoracic biopsy groups. Rapid on-site cytological evaluations were performed to guide adjustments to biopsy target areas. The primary outcome was the diagnostic yield, defined as the proportion of biopsies yielding a specific benign or malignant diagnosis on cytology or histology. Secondary outcomes included biopsy duration and the combined incidence of post-biopsy complications.
Results: From May 2019 to June 2023, a total of 413 patients were randomised. Ultimately, 205 patients in the SWE group and 206 in the conventional group were included in the intention-to-diagnose analysis. The SWE group achieved a significantly higher diagnostic yield compared with the conventional group (94.6% versus 88.3%; risk ratio 1.07, 95% CI 1.01-1.14; p=0.02) and a shorter biopsy duration (median (interquartile range) 12 (9-15) versus 13 (10-18) min; Hodges-Lehmann median difference -1.0 (95% CI -3.0-0) min; p=0.003). The combined incidence of pneumothorax, haemoptysis and haemothorax was comparable between the groups (2.4% versus 2.9%; risk ratio 0.84, 95% CI 0.26-2.70; p=0.77).
Conclusions: SWE-guided transthoracic biopsy increased the diagnostic yield and reduced the biopsy duration for subpleural lung lesions without increasing the risk of complications.
背景：经胸横波弹性成像（SWE）有助于良恶性病变的鉴别。这项实用的随机对照试验旨在验证超声引导下经胸活检诊断胸膜下肺病变的有效性和安全性。方法：将符合条件的肺周围病变疑似恶性肿瘤且适合活检的患者按1:1的比例随机分为超声引导下或常规超声引导下的经胸活检组。快速现场细胞学评估进行指导调整活检靶区。主要结果是诊断率，定义为细胞学或组织学上产生特定良性或恶性诊断的活检比例。次要结局包括活检时间和活检后并发症的综合发生率。结果：2019年5月至2023年12月，共纳入413例患者。最终，205例SWE组患者和206例常规组患者被纳入意向诊断分析。与常规组相比，SWE组的诊断率明显更高（94.6% vs 88.3%；风险比：1.07;95% CI: 1.01-1.14; p=0.02），活检时间更短(中位12分钟[9-15]对13分钟[10-18]；Hodges-Lehmann中位差为-1.0分钟（95% CI: -3.0-0）；p = 0.003)。气胸、咯血和血胸的合并发生率在两组间具有可比性（2.4% vs 2.9%；风险比：0.84;95% CI: 0.26-2.70; p=0.77）。结论：超声引导下的经胸活检提高了胸膜下肺病变的诊断率，缩短了活检时间，但未增加并发症的风险。
{"title":"Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial.","authors":"Yao-Wen Kuo, Yen-Lin Chen, Yung-Hsuan Chen, Yih-Leong Chang, I-Shiow Jan, Chen-Tu Wu, Min-Shu Hsieh, Chun-Kai Huang, Huey-Dong Wu, Chi-Tai Fang, Hao-Chien Wang","doi":"10.1183/13993003.02370-2024","DOIUrl":"10.1183/13993003.02370-2024","url":null,"abstract":"<p><strong>Background: </strong>Transthoracic shear-wave elastography (SWE) facilitates differentiation between benign and malignant lesions. This pragmatic randomised controlled trial aimed to validate the effectiveness and safety of SWE-guided transthoracic biopsy for diagnosing subpleural lung lesions.</p><p><strong>Methods: </strong>Eligible patients with peripheral lung lesions suspicious for lung malignancy and suitable for biopsy were randomised in a 1:1 ratio to the SWE-guided or conventional ultrasound-guided transthoracic biopsy groups. Rapid on-site cytological evaluations were performed to guide adjustments to biopsy target areas. The primary outcome was the diagnostic yield, defined as the proportion of biopsies yielding a specific benign or malignant diagnosis on cytology or histology. Secondary outcomes included biopsy duration and the combined incidence of post-biopsy complications.</p><p><strong>Results: </strong>From May 2019 to June 2023, a total of 413 patients were randomised. Ultimately, 205 patients in the SWE group and 206 in the conventional group were included in the intention-to-diagnose analysis. The SWE group achieved a significantly higher diagnostic yield compared with the conventional group (94.6% <i>versus</i> 88.3%; risk ratio 1.07, 95% CI 1.01-1.14; p=0.02) and a shorter biopsy duration (median (interquartile range) 12 (9-15) <i>versus</i> 13 (10-18) min; Hodges-Lehmann median difference -1.0 (95% CI -3.0-0) min; p=0.003). The combined incidence of pneumothorax, haemoptysis and haemothorax was comparable between the groups (2.4% <i>versus</i> 2.9%; risk ratio 0.84, 95% CI 0.26-2.70; p=0.77).</p><p><strong>Conclusions: </strong>SWE-guided transthoracic biopsy increased the diagnostic yield and reduced the biopsy duration for subpleural lung lesions without increasing the risk of complications.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-12DOI: 10.1183/13993003.02404-2025
Shelton Lo,Gabriel A Goodney,Hantao Wang,Jungeun Lim,Susan Valerie Czach,Jared A Fisher,Maryam Hashemian,Véronique L Roger,Rena R Jones,Jason Y Y Wong
{"title":"Ozone and risk of chronic obstructive pulmonary disease in the united states: demographic insights from the all of us research program.","authors":"Shelton Lo,Gabriel A Goodney,Hantao Wang,Jungeun Lim,Susan Valerie Czach,Jared A Fisher,Maryam Hashemian,Véronique L Roger,Rena R Jones,Jason Y Y Wong","doi":"10.1183/13993003.02404-2025","DOIUrl":"https://doi.org/10.1183/13993003.02404-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"56 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-12DOI: 10.1183/13993003.01272-2025
Jonathan R Baker,Delphine Beaulieu,Edibe Avci,Eileen Huang,Oliver Eickelberg,Silke Meiners,Rajkumar Savai,Mareike Lehmann,Melanie Königshoff
Aging is a crucial factor in the development of chronic lung diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer. Marking the 10th anniversary of the original "Hallmarks of the aging lung" published in this Journal, we present an updated review highlighting key cellular and molecular features of aging that drive the onset and progression of these conditions. Aging stands as the most significant risk factor for chronic lung diseases, which are characterised by structural and functional changes such as reduced elasticity, persistent inflammation, and impaired repair capacity. Recent evidence confirms that nearly all recognised hallmarks of aging play a role in the pathogenesis of these diseases. Notably, extracellular matrix (ECM) dysregulation - first proposed as a lung aging hallmark in 2015 - has become an integral aspect of aging in lung disease. Environmental exposures, such as cigarette or wildfire smoke, accelerate age-related changes by increasing oxidative stress, promoting cellular senescence, and disrupting tissue homeostasis. In lung cancer, aging contributes to genomic alterations, epigenetic dysregulation, immune evasion, and therapeutic resistance. Additionally, the roles of extracellular vesicles and microbiome changes in shaping these aging phenotypes are emerging areas of research. Early clinical studies are now targeting specific aging hallmarks, such as cellular senescence, with the goal of reducing age-related pathology and improving outcomes. Overall, integrating aging biology into lung disease research paves the way for innovative diagnostic and therapeutic strategies that address common molecular mechanisms across multiple chronic lung conditions.
{"title":"Hallmarks of the ageing lung - 10 years later.","authors":"Jonathan R Baker,Delphine Beaulieu,Edibe Avci,Eileen Huang,Oliver Eickelberg,Silke Meiners,Rajkumar Savai,Mareike Lehmann,Melanie Königshoff","doi":"10.1183/13993003.01272-2025","DOIUrl":"https://doi.org/10.1183/13993003.01272-2025","url":null,"abstract":"Aging is a crucial factor in the development of chronic lung diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer. Marking the 10th anniversary of the original \"Hallmarks of the aging lung\" published in this Journal, we present an updated review highlighting key cellular and molecular features of aging that drive the onset and progression of these conditions. Aging stands as the most significant risk factor for chronic lung diseases, which are characterised by structural and functional changes such as reduced elasticity, persistent inflammation, and impaired repair capacity. Recent evidence confirms that nearly all recognised hallmarks of aging play a role in the pathogenesis of these diseases. Notably, extracellular matrix (ECM) dysregulation - first proposed as a lung aging hallmark in 2015 - has become an integral aspect of aging in lung disease. Environmental exposures, such as cigarette or wildfire smoke, accelerate age-related changes by increasing oxidative stress, promoting cellular senescence, and disrupting tissue homeostasis. In lung cancer, aging contributes to genomic alterations, epigenetic dysregulation, immune evasion, and therapeutic resistance. Additionally, the roles of extracellular vesicles and microbiome changes in shaping these aging phenotypes are emerging areas of research. Early clinical studies are now targeting specific aging hallmarks, such as cellular senescence, with the goal of reducing age-related pathology and improving outcomes. Overall, integrating aging biology into lung disease research paves the way for innovative diagnostic and therapeutic strategies that address common molecular mechanisms across multiple chronic lung conditions.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"8 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-12DOI: 10.1183/13993003.02384-2025
Richard Beasley,Jonathan Noble
{"title":"Time to establish a consensus definition of clinical remission distinct from well-controlled asthma.","authors":"Richard Beasley,Jonathan Noble","doi":"10.1183/13993003.02384-2025","DOIUrl":"https://doi.org/10.1183/13993003.02384-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"33 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-12DOI: 10.1183/13993003.02574-2025
David M G Halpin, Sanja Stanojevic, Meredith C McCormack, Dave Singh, David Kamkinsky, Claus F Vogelmeier, Laura Gochicoa-Rangel, Alvar Agusti, Brendan Cooper
{"title":"Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD.","authors":"David M G Halpin, Sanja Stanojevic, Meredith C McCormack, Dave Singh, David Kamkinsky, Claus F Vogelmeier, Laura Gochicoa-Rangel, Alvar Agusti, Brendan Cooper","doi":"10.1183/13993003.02574-2025","DOIUrl":"10.1183/13993003.02574-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：